XG 104

Drug Profile

XG 104

Alternative Names: XG-104

Latest Information Update: 22 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xigen
  • Class Eye disorder therapies
  • Mechanism of Action JNK mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry eyes
  • Preclinical Unspecified

Most Recent Events

  • 22 Dec 2016 Phase-II development is ongoing in USA (Xigen pipeline, December 2016)
  • 22 Dec 2016 Preclinical trials in Undefined indication in Switzerland (Xigen pipeline)
  • 01 Feb 2015 Xigen completes a phase II trial in Dry eyes in USA (NCT02235259)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top